Volume 5, Supplement 2SupplementInitial Experience with Single-Agent Docetaxel as Neoadjuvant Therapy in Men with Locally Advanced Prostate CancerRobert DreicerEric A KleinLocally advanced prostate cancerRadical prostatectomyNeoadjuvant
Volume 5, Supplement 3SupplementInitial Experience with Single-Agent Docetaxel as Neoadjuvant Therapy in Men with Locally Advanced Prostate CancerRobert DreicerEric A KleinLocally advanced prostate cancerRadical prostatectomyNeoadjuvant
Volume 22, Number 3Review ArticlesCurrent and Future Management of Locally Advanced and Metastatic Prostate CancerOriginal ResearchNeal D ShoreWith increasing treatment options available, the management of locally advanced and metastatic prostate cancer (PCa) is growing more complex, nuanced, and individualized. Strategies for combining surgery, radiation, chemotherapy, and androgen deprivation therapy (ADT) continue to evolve, as do ADT and immunotherapy options. Additionally, multiple adjunctive agents for metastatic PCa have been recently approved or are pending approval. As the number of locally advanced and metastatic prostate cancers being diagnosed rises, so does the need to consider patients’ clinical situations and personal preferences. This review discusses current and potential future approaches to managing locally advanced and metastatic PCa. [Rev Urol. 2020;22(3):110-123] © 2020 MedReviews®, LLCProstate cancerChemotherapyAndrogen deprivation therapyMetastatic prostate cancerLocally advanced prostate cancer